In this issue of , Lamy et al present the results of the LYSA/GOELAMS trial 02-03, where patients with limited-stage diffuse large B-cell lymphoma (DLBCL) received either 4 or 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) based on risk stratification, and those achieving complete response (CR) by positron emission tomography (PET) after 4 cycles either received 40 Gy of radiation or were observed. The outcomes were excellent regardless of radiation administration, which was not surprising because the study enrolled a favorable-risk cohort of patients. The role of radiation therapy (RT) is hard to discern in this setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757692 | PMC |
| http://dx.doi.org/10.1182/blood-2017-11-813915 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological and genetic analyses of thyroid large B-cell lymphoma in a Japanese population.
J Clin Exp Hematop
December 2024
Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
Article Synopsis
- Primary thyroid lymphoma, a rare cancer primarily consisting of large B-cell lymphomas (LBCLs), has a favorable prognosis and its underlying reasons are being studied.
- Analysis of 21 cases revealed that most patients (71%) had limited-stage disease and a 5-year overall survival rate of 83%, with no central nervous system recurrences observed.
- Factors linked to better clinical outcomes included a higher percentage of germinal center B-cell (GCB) phenotypes and an absence of MYD88 mutations among the cases.
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35).
Hematol Oncol
November 2024
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Article Synopsis
- Primary lymphoma of the female genital tract (PLFGT) is an uncommon type of lymphoma, with a study involving 60 women revealing that many cases were diagnosed around their early 50s.
- The uterus and ovaries were the most frequently affected sites, and diffuse large B-cell lymphoma (DLBCL) was the predominant subtype found in the majority of patients.
- The study indicated a median overall survival of approximately 13 years for DLBCL patients, with advanced disease stage correlating to a poorer prognosis, while CNS relapses were notably linked to patients with ovarian involvement who did not receive prophylactic treatment.
Key Clinical Message: Primary gastric diffuse large B-cell lymphoma (DLBCL), a rare malignancy linked to () infection, in this case regressed to low-grade lymphoma and then achieved complete remission after eradication (E), highlighting this unique interim change and the potential of E as an effective treatment for early-stage cases.
Abstract: Primary gastric diffuse large B-cell lymphoma (DLBCL) is a rare malignancy. Like gastric mucosa-associated lymphoid tissue (MALT) lymphoma, infection is implicated in lymphomagenesis and has thus emerged as a therapeutic target.
Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China.
Ann Hematol
October 2024
Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, 610041, P.R. China.
Approximately 40% of limited-stage (stage I and II) diffuse large B-cell lymphoma (LS-DLBCL) presents with extranodal disease. Extranodal LS-DLBCL may have significant biological differences and associated with worse outcomes than nodal disease. Although rituximab based chemoimmunotherapy is standard of first-line treatment, the role of consolidative radiotherapy (RT) in this particular subgroup is controversial.
View Article and Find Full Text PDFEvent-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
Haematologica
November 2024
North Japan Hematology Study Group (NJHSG); Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo.
Information regarding follow-up duration after treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) is important. However, a clear endpoint has yet to be established. We enrolled a total of 2,182 patients newly diagnosed with DLBCL between 2008 and 2018.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!